Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In

Status Completed

Clinical Trial Summary

The hypothesis of this study is that the natural supplement Capros will decrease LDL levels, platelet aggregation, and serum concentrations of high sensitivity C-reactive protein in humans at risk for cardiovascular disease.

Clinical Trial Description

A non-randomized, longitudinal study to determine the effect of Capros supplementation on a lipid profile, platelet aggregation and high-sensitivity C - reactive protein in 30 volunteers at risk for cardiovascular disease.

-Herbal Polyphenols/Antioxidants: Role in Cardiovascular Disease Prevention: Phenolic compounds are dietary antioxidants found in plants that are shown to inhibit LDL oxidation, inhibit platelet aggregation and adhesion, decrease total and LDL cholesterol, and induce endothelium-dependent vaso-relaxation. [Lapointe, Vita, and Mendes]. Epidemiologic studies suggest that higher polyphenol intake from fruits and vegetables is associated with decreased risk for cardiovascular disease. Among the numerous plausible mechanisms by which polyphenols may offer cardiovascular protection, improvement of the endothelial function and inhibition of angiogenesis and cell migration and proliferation in blood vessels have been the focuses of recent studies. Antioxidants in polyphenols, in addition to protecting LDL cholesterol against oxidation, may act at a vascular cell level by limiting cellular production of reactive oxygen species, and, thus, cell-mediated LDL oxidation. In traditional Indian medicine, the gooseberry (Phyllanthus emblica) has been used for thousands of years as an effective source of polyphenols and antioxidants. "P. emblica is considered beneficial against various diseases namely cancer, diabetes, liver treatment, and various other diseases."[Hiraganahalli]. Capros®, from Natreon, Inc., is a cascading antioxidant ingredient derived from Phyllanthus emblica. It has been used in cosmetics and food-and-beverage formulations in many countries, and, based on extensive scientific research, also shows particular promise as a dietary supplement. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01858376
Study type	Interventional
Source	Ohio State University
Contact
Status	Completed
Phase	N/A
Start date	March 2013
Completion date	January 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00001154` - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Completed	`NCT02927184` - Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease	Phase 2
Completed	`NCT04640012` - Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics of DC371739 Single-Dose Treatment in Healthy Subjects	Phase 1
Completed	`NCT03213288` - Bilberry Fruit and Black Rice Derived Anthocyanins on Lipid Status	N/A
Completed	`NCT00382564` - Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease	N/A
Recruiting	`NCT02979704` - A Comparative Study of Rosuvastatin and Atorvastatin in Patients With Hyperlipidemia	Phase 2/Phase 3
Completed	`NCT02569814` - A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin	Phase 1
Completed	`NCT02280590` - Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia	Phase 4
Completed	`NCT02428998` - Safety for 24 Weeks Intake of Korean Red Ginseng in Adults	N/A
Completed	`NCT01678183` - Financial Incentives for Medication Adherence	N/A
Completed	`NCT01694446` - Regulation of Intestinal and Hepatic Lipoprotein Production by Glucose and Fructose	N/A
Completed	`NCT01426412` - A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol	Phase 1
Completed	`NCT01131832` - Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols	Phase 4
Completed	`NCT00758303` - A Study to Evaluate the Lipid Regulating Effects of TRIA-662	Phase 2/Phase 3
Completed	`NCT00534105` - Lipid Metabolism in Gestational Diabetes	N/A
Recruiting	`NCT00408824` - Investigation of Genetic Risk of Metabolic Syndrome in Company Employee (NGK Study)	N/A
Completed	`NCT00362206` - Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin	Phase 3
Terminated	`NCT00299169` - Randomized Trial Comparing N of 1 Trials to Standard Practice to Improve Adherence to Statins in Patients With Diabetes	Phase 4
Completed	`NCT00414986` - Using Learning Teams for Reflective Adaptation for Diabetes and Depression	N/A
Completed	`NCT00381992` - Risk Assessment of Long-Haul Truck Drivers	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans — Capros

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms